PTC Deferred Long Term Liab from 2010 to 2024
| PTCT Stock | USD 42.99 0.24 0.56% |
Deferred Long Term Liabilities | First Reported 2013-06-30 | Previous Quarter 102.8 M | Current Value 51.9 M | Quarterly Volatility 63.6 M |
Check PTC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PTC Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 135.6 M, Total Revenue of 984.7 M or Research Development of 699.9 M, as well as many indicators such as Price To Sales Ratio of 2.09, Dividend Yield of 0.0 or Days Sales Outstanding of 51.74. PTC financial statements analysis is a perfect complement when working with PTC Therapeutics Valuation or Volatility modules.
PTC | Deferred Long Term Liab |
Latest PTC Therapeutics' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of PTC Therapeutics over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. PTC Therapeutics' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PTC Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
PTC Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 55,178,376 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 111.94 | |
| Mean Deviation | 57,584,801 | |
| Median | 7,954,000 | |
| Standard Deviation | 61,766,129 | |
| Sample Variance | 3815.1T | |
| Range | 137.1M | |
| R-Value | 0.79 | |
| Mean Square Error | 1541.7T | |
| R-Squared | 0.62 | |
| Significance | 0.0005 | |
| Slope | 10,916,630 | |
| Total Sum of Squares | 53410.8T |
PTC Deferred Long Term Liab History
About PTC Therapeutics Financial Statements
PTC Therapeutics shareholders use historical fundamental indicators, such as Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although PTC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in PTC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on PTC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 118.3 M | 70.3 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.